Efficacy of Getong Tongluo Capsule (葛酮通络胶囊) for Convalescent-Phase of Ischemic Stroke and Primary Hypertension: A Multicenter, Randomized, Double-Blind, Controlled Trial

Qian-yu ZHAO; Rong-hua TANG; Guo-xiong LU; Xu-zheng CAO; Lu-ran LIU; Ji-hua ZHANG; Jin-tao ZHANG; Bin XU; Hong-tao WEI; Miao YANG; Ling WEI; Mei ZHANG; Wen-zong ZHU; Hong WANG; Hong-lin LI; Li-ping MA; Chi ZHONG; Yan-jie GAO; Na ZHANG; Shan REN; Lu CHEN; Yun-hai LIU; Zhi-gang CHEN

doi:10.1007/s11655-020-3320-3

Your Location：

Home >

Browse articles >

Efficacy of Getong Tongluo Capsule (葛酮通络胶囊) for Convalescent-Phase of Ischemic Stroke and Primary Hypertension: A Multicenter, Randomized, Double-Blind, Controlled Trial

Original Article | Updated：2021-08-16

- Efficacy of Getong Tongluo Capsule (葛酮通络胶囊) for Convalescent-Phase of Ischemic Stroke and Primary Hypertension: A Multicenter, Randomized, Double-Blind, Controlled Trial
- Chinese Journal of Integrative Medicine Vol. 27, Issue 4, Pages: 252-258(2021)
- Affiliations：
  
  1.Department of Neurology, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing (100078), China
  2.The Second School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing (100029), China
  3.Department of Neurology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan (430030), China
  4.Department of Neurology, the Hospital Affiliated to Jiangxi University of Traditional Chinese Medicine, Nanchang (330006), China
  5.Department of Neurology, the 211th Hospital of the People's Liberation Army, Harbin (150000), China
  6.Department of Neurology, the Fourth Hospital Affiliated to Harbin Medical University, Harbin (150000), China
  7.Department of Neurology, the First Hospital of Suihua, Suihua, Heilongjiang Province(152053), China
  8.Department of Neurology, the 88th Hospital of the People's Liberation Army, Tai'an, Shandong Province (271000), China
  9.Department of Neurology, Xinhua Hospital of Zhejiang Province, Hangzhou (310005), China
  10.Department of Neurology, the Second Provincial People's Hospital of Gansu, Lanzhou (730000), China
  11.Department of Neurology, People's Hospital of Bozhou, Bozhou, Anhui Province (236800), China
  12.Department of Neurosurgery, the Third Hospital Affiliated to Shanxi University of Chinese Medicine, Taiyuan (030000), China
  13.Department of Neurology, the First People's Hospital of Huainan, Huainan, Anhui Province (232007), China
  14.Department of Neurology, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou, Zhejiang Province (325000), China
  15.Department of Neurology, the First Hospital Affiliated to Medical College of Shihezi University, Shihezi, Xinjiang Uygur Autonomous Region(832008), China
  16.Department of Rehabilitation, the Second Hospital Affiliated to Heilongjiang University of Traditional Chinese Medicine, Harbin (150001), China
  17.Department of Neurology, People's Hospital of Xinzhou, Xinzhou, Shanxi Province (034000), China
  18.Department of Neurology, People's Hospital of Weifang, Weifang, Shandong Province(261000), China
  19.Department of Neurology, Xiangya Hospital Affiliated to Central South University, Changsha (410013), China
- Author bio：
  
  Correspondence to: Prof. CHEN Zhi-gang, E-mail: chenzhigang64@126.com
- Funds：
- DOI：10.1007/s11655-020-3320-3
  CLC：
- Published：01 April 2021，
  
  Published Online：10 October 2020，
  
  Accepted：04 March 2020
Scan for full text
Qian-yu ZHAO, Rong-hua TANG, Guo-xiong LU, et al. Efficacy of Getong Tongluo Capsule (葛酮通络胶囊) for Convalescent-Phase of Ischemic Stroke and Primary Hypertension: A Multicenter, Randomized, Double-Blind, Controlled Trial. [J]. Chinese Journal of Integrative Medicine 27(4):252-258(2021)
DOI：

Qian-yu ZHAO, Rong-hua TANG, Guo-xiong LU, et al. Efficacy of Getong Tongluo Capsule (葛酮通络胶囊) for Convalescent-Phase of Ischemic Stroke and Primary Hypertension: A Multicenter, Randomized, Double-Blind, Controlled Trial. [J]. Chinese Journal of Integrative Medicine 27(4):252-258(2021) DOI： 10.1007/s11655-020-3320-3.

摘要

Abstract

Objective:

To evaluate whether the efficacy of Getong Tongluo Capsule (葛酮通络胶囊

GTC

consisted of total flavone of

Radix Puerariae

) on improving patients' quality of life and lowering blood pressure are superior to the extract of

Ginkgo biloba

(EGB) for patients with convalescent-phase ischemic stroke and primary hypertension.

Methods:

This randomized

positive-drug- and placebo-controlled

double-blind trial was conducted from September 2015 to October 2017. Totally 477 eligible patients from 18 hospitals in China were randomly assigned in a 2:1:1 ratio to the following interventions

twice a day for 12 weeks: (1) GTC 250 mg plus EGB-matching placebo 40 mg (237 cases

GTC group)

(2) EGB 40 mg plus GTC-matching placebo 250 mg (120 cases

EGB group) or (3) GTC-matching placebo 250 mg plus EGB-matching placebo 40 mg (120 cases

placebo group). Moreover

all patients were orally administered aspirin enteric-coated tablets 100 mg

once a day for 12 weeks. The primary outcome was the Barthel Index (BI). The secondary outcomes included the control rate of blood pressure and National Institutes of Health Stroke Scale (NIHSS) scores. The incidence and severity of adverse events (AEs) were calculated and assessed.

Results:

The BI relative independence rates

the clinical recovery rates of NIHSS

and the total effective rates of NIHSS in the GTC and EGB groups were significantly higher than the placebo group at 12 weeks after treatment (

0.05)

and no statistical significance was found between the GTC and EGB groups (

0.05). The control rate of blood pressure in the GTC group was significantly higher than the EGB and placebo groups at 12

18 and 24 weeks after treatment (

0.01). There were no statistically significant differences in the incidences of AEs

adverse drug reactions

or serious AEs among the 3 groups (

0.05).

Conclusion:

GTC exhibited significant efficacy in improving patients' quality of life as well as neurological function and controlling hypertension. (Registration No. ChiCTR1800016667)

关键词

Keywords

convalescent-phase of ischemic strokeprimary hypertensionGetong Tongluo Capsuletotal flavone of Radix Puerariaerandomized controlled trialChinese medicine

references

Guzik A, Bushnell C. Stroke epidemiology and risk factor management. Continuum (Minneapolis, Minn) 2017;23:15-39.

Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003;2:43-53.

Donnan GA, Fisher M, Macleod M, Davis SM. Stroke.Lancet 2008;371:1612-1623.

Gaire , Prasad B. Herbal medicine in ischemic stroke: challenges and prospective. Chin J Integr Med 2018;24:243-246.

Hui C. Integrative medicine on optimizing clopidogrel and aspirin therapy. Chin J Integr Med 2019;25:77-82.

Pistoia F, Sacco S, Degan D, Tiseo C, Ornello R, Carolei A. Hypertension and stroke: epidemiological aspects and clinical evaluation. High Blood Press Cardiovasc Prev 2016;23:9-18.

Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders.Neurotherapeutics 2019;16:666-674.

Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327-1332.

Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects. Phytother Res 2014;28:961-975.

National Pharmacopoeia Committee. Pharmacopoeia of People's Republic of China. Part 1. Chin Med Sci Press;2010:333.

Alesheikh P, Mashoufi A, Tang HL, Zhang W, Di B, Yan YY, et al. Chinese herbal formula Tongluo Jiunao Injection protects against cerebral ischemia by activating neurotrophin 3/tropomyosin-related kinase C pathway.Neural Regen Res 2015;10:445-450.

Liu B, Tan Y, Wang D, Liu M. Puerarin for ischaemic stroke.Cochrane Database Syst Rev 2016;2:Cd004955.

Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med 2017;167:112-121.

Group of Cerebrovascular Disease, Branch Association of Neurology, Chinese Medical Association. Guidelines of diagnosis and treatment of acute ischemic stroke in China(2014 version). Chin J Neurol (Chin) 2015;48:246-255.

Bamford J, Sandercock P, Dennis M, Burn J, Warlow C.Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-1526.

Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol 1989;46:660-662.

Rankin J. Cerebral vascular accidents in patients over the age of 60. Ⅱ. Prognosis. Scott Med J 1957;2:200-215.

Zhou S, Huang JB, Li YS, Cui L, Wang LP, Bao YC, et al.Phase Ⅱ clinical study on Getong Tongluo Capsule in cerebral infarction patients with blood stasis blockage context. Mod J Integr Tradit Chin West Med (Chin) 2013;22:2514-2517.

Quinn TJ, Langhorne P, Stott DJ. Barthel index for stroke trials: development, properties, and application. Stroke 2011;42:1146-1151.

Lim DW, Lee C, Kim IH, Kim YT. Anti-inflammatory effects of total isoflavones from Pueraria lobata on cerebral ischemia in rats. Molecules 2013;18:10404-10412.

Chiang HM, Fang SH, Wen KC, Hsiu SL, Tsai SY, Hou YC, et al. Life-threatening interaction between the root extract of Pueraria lobata and methotrexate in rats. Toxicol Appl Pharmacol 2005;209:263-268.

Zhang L. Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine. Drug Deliv 2019;26:860-869.

Nash KM, Shah ZA. Current perspectives on the beneficial role of Ginkgo biloba in neurological and cerebrovascular disorders. Integr Med Insights 2015;10:1-9.

Tian J, Liu Y, Chen K. Ginkgo biloba extract in vascular protection: molecular mechanisms and clinical applications.Curr Vasc Pharmacol 2017;15:532-548.

Tan MS, Yu JT, Tan CC, Wang HF, Meng XF, Wang C, et al. Efficacy and adverse effects of Ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis 2015;43:589-603.

Xu X, Zhang S, Zhang L, Yan W, Zheng X. The neuroprotection of puerarin against cerebral ischemia is associated with the prevention of apoptosis in rats. Planta Med 2005;71:585-591.

Li X, Zhang D, Bai Y, Xiao J, Jiao H, He R. Ginaton improves neurological function in ischemic stroke rats via inducing autophagy and maintaining mitochondrial homeostasis. Neuropsychiatr Dis Treat 2019;15:1813-1822.

Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs 2006;66:133-144.

Cai RL, Li M, Xie SH, Song Y, Zou ZM, Zhu CY, et al.Antihypertensive effect of total flavone extracts from Puerariae Radix. J Ethnopharmacol 2011;133:177-183.

Guan T, Ma J, Li M, Xue T, Lan Z, Guo J, et al. Rapid transitions in the epidemiology of stroke and its risk factors in China from 2002 to 2013. Neurology 2017;89:53-61.

Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al.Prevalence, incidence, and mortality of stroke in China:results from a nationwide population-based survey of 480 687 adults. Circulation 2017;135:759-771.

Parsons C, Murad MH, Andersen S, Mookadam F, Labonte H. The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis. Future Cardiol 2016;12:237-248.

Ng CF, Koon CM, Cheung DW, Lam MY, Leung PC, Lau CB, et al. The anti-hypertensive effect of Danshen(Salvia miltiorrhiza) and Gegen (Pueraria lobata) formula in rats and its underlying mechanisms of vasorelaxation. J Ethnopharmacol 2011;137:1366-1372.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Efficacy of Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B Cirrhosis/Liver Fibrosis: A Randomized Double-Blind Controlled Trial

Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents: A Randomized Controlled Trial

Related Author

No data

Related Institution

Department of Endocrinology, Guangdong Provincial Hospital of Chinese Medicine

The Second Clinical College of Guangzhou University of Chinese Medicine

Department of Endocrinology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Guangdong Provincial Academy of Chinese Medical Sciences

Department of Endocrinology, The First Affiliated Hospital of Henan University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰